StreetInsider.com News Articles

Form 144 CARLSMED, INC. Filed by: Greenstein Leonard M.

Wed, 14 Oct 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20261014/27186920.html

Carlsmed launches lumbar spine system at NASS annual meeting

Wed, 14 Oct 2026 09:01:34 -0400

Carlsmed, Inc. (Nasdaq: CARL) announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting in San Antonio, Texas.

The launch follows a limited market evaluation that began in February 2026, with the first procedure completed on February 10, 2026. The system is designed to support a direct posterior approach for spinal fusion, using AI-enabled software to generate surgeon-specific three-dimensional surgical plans and patient-specific fusion devices.

"The launch of the Bi-lateral System further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion," said Mike Cordonnier, Chairman

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

Wed, 14 Oct 2026 09:00:00 -0400

CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo^® Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41^st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026.

“The launch of the Bi-lateral System further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion,” said Mike Cordonnier, Chairman and CEO of Carlsmed.

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

Wed, 14 Oct 2026 09:00:00 -0400

Form 4 CARLSMED, INC. For: Oct 05 Filed by: Bertolini Jeffrey

Tue, 06 Oct 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20261006/27156219.html

Form 144 CARLSMED, INC. Filed by: Bertolini Jeffrey

Mon, 05 Oct 2026 14:16:00 -0400

si-local-file:///var/storage/secattach/20261005/27148218.html

Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment.

The Company further announced that on October 1, 2026, it granted stock options to purchase 132,464 shares of the Company’s common stock and 63,735 time-based RSUs to Anthony

Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

The Company further announced that on October 1, 2026, it granted stock options to purchase 132,464 shares of the Company’s common stock and 63,735 time-based RSUs to Anthony

Form 4 CARLSMED, INC. For: Sep 30 Filed by: Bertolini Jeffrey

Thu, 01 Oct 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20261001/27137404.html

Form S-8 CARLSMED, INC.

Thu, 01 Oct 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20261001/27137345.html

Carlsmed names former Intuitive Surgical executive as chief AI officer

Thu, 01 Oct 2026 09:01:39 -0400

Carlsmed, Inc. (Nasdaq: CARL) has appointed Tony Jarc as Chief Product and AI Officer, a newly created position, effective Oct. 1, 2026, according to a press release from the Carlsbad, Calif.-based medical technology company.

Dr. Jarc joins Carlsmed from Intuitive Surgical, where he served most recently as Vice President of Digital Products and Machine Learning Insights. During more than 15 years at Intuitive Surgical, he built the company's global AI organization and developed clinical AI products. He holds a Ph.D. in Biomedical Engineering from Northwestern University and a Bachelor of Science in Mechanical Engineering from Cornell University.

In his new role, Dr.

Carlsmed names former Intuitive Surgical executive as chief AI officer

Thu, 01 Oct 2026 09:01:39 -0400

In his new role, Dr.

Carlsmed Appoints Tony Jarc as Chief Product and AI Officer

Thu, 01 Oct 2026 09:00:00 -0400

CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company’s next generation technology platform, surgical UI/UX, and personalized spine surgery procedures.

“Tony’s addition comes at a pivotal moment as we transform our technology platform to scale and advance our patient-centric innovation for our highly differentiated personalized surgery business,"

Carlsmed Appoints Tony Jarc as Chief Product and AI Officer

Thu, 01 Oct 2026 09:00:00 -0400

Form 3 CARLSMED, INC. For: Sep 24 Filed by: Kamocsay Jennifer

Wed, 30 Sep 2026 19:51:00 -0400

si-local-file:///var/storage/secattach/20260930/27129863.html

Form 4 CARLSMED, INC. For: Sep 28 Filed by: Heppenstall Richard

Wed, 30 Sep 2026 19:38:00 -0400

si-local-file:///var/storage/secattach/20260930/27129855.html

Form 3 CARLSMED, INC. For: Sep 28 Filed by: Heppenstall Richard

Wed, 30 Sep 2026 19:37:00 -0400

si-local-file:///var/storage/secattach/20260930/27129854.html

Form 144 CARLSMED, INC. Filed by: Bertolini Jeffrey

Wed, 30 Sep 2026 11:14:00 -0400

si-local-file:///var/storage/secattach/20260930/27127192.html

Form 8-K CARLSMED, INC. For: Sep 24

Wed, 30 Sep 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260930/27126464.html

Carlsmed names new CFO, reaffirms 2026 revenue guidance

Mon, 28 Sep 2026 08:30:20 -0400

Carlsmed, Inc. (Nasdaq: CARL) announced the appointment of Richard Heppenstall as Chief Financial Officer, effective immediately, replacing Leo Greenstein, who served in the role since 2023 and is departing to pursue other professional interests.

Heppenstall brings nearly 30 years of experience in healthcare, life sciences, and technology. He most recently served as Executive Vice President, CFO, and Treasurer of ZimVie Inc. from September 2021 until its acquisition by ArchiMed SAS in October 2025. Before that, he served as CFO of Breg, Inc. from April 2019 to September 2021, and as Senior Vice President of Finance and Treasury at Orthofix Medical Inc.

Carlsmed Appoints Richard Heppenstall as Chief Financial Officer

Mon, 28 Sep 2026 08:30:00 -0400

Company Reaffirms Fiscal Year 2026 Guidance

CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be leaving Carlsmed to pursue other professional interests.

“We are excited to welcome Rich to Carlsmed at a pivotal point for the Company,” said Mike Cordonnier, Chairman and CEO. “He is a proven leader with the deep

Carlsmed Appoints Richard Heppenstall as Chief Financial Officer

Mon, 28 Sep 2026 08:30:00 -0400

Company Reaffirms Fiscal Year 2026 Guidance

“We are excited to welcome Rich to Carlsmed at a pivotal point for the Company,” said Mike Cordonnier, Chairman and CEO. “He is a proven leader with the deep

Carlsmed sues DeGen Medical over eight patent violations

Tue, 15 Sep 2026 19:00:11 -0400

Carlsmed, Inc. (Nasdaq: CARL) filed a patent infringement lawsuit against DeGen Medical, Inc. in the United States District Court for the District of South Carolina Florence Division, according to a press release issued Sept. 15, 2026.

The complaint alleges that DeGen Medical is infringing eight of Carlsmed's patents related to implants, methods, and systems. Carlsmed is seeking injunctive relief and monetary damages.

"Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing value to patients, surgeons, and payors every day. We are committed to protecting the intellectual property that supports our

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Tue, 15 Sep 2026 19:00:00 -0400

CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.

The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement.

“Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Tue, 15 Sep 2026 19:00:00 -0400

The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement.

“Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and